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Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with common comorbidities that include opposi-
tional defiant disorder, conduct disorder, anxiety disorder, and affective disorders. Because of these comorbidities, drug combi-
nation treatments and drug-drug interactions are becoming increasingly more frequent. The present case report describes an 
acute dystonic reaction following the abrupt discontinuation of methylphenidate from a drug regimen with risperidone. The patient 
experienced acute dystonic reactions on three separate occasions when he forgot to take his methylphenidate medication. The 
present report informs clinicians about the possible side effects, such as dystonia, when psychostimulant and antipsychotic drug 
combinations are altered and suggests that the abrupt cessation of stimulants may lead to the development of movement 
disorders. Therefore, appropriate care is necessary when changing the dose of a drug or abruptly discontinuing a drug from 
a combination of psychostimulants and antipsychotics.
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INTRODUCTION
The use of atypical antipsychotics in conjunction with 
stimulants is becoming an increasingly more frequent op-
tion for the treatment of attention-deficit/hyperactivity 
disorder (ADHD).1) However, if the stimulant medication 
is removed from a treatment regime that includes an atyp-
ical antipsychotic agent, it is possible that an acute dys-
tonic reaction (ADR) may occur, albeit rarely.2) Only four 
cases of dystonic reactions following the interruption of 
stimulant use during a regimen of a stimulant and an atyp-
ical antipsychotic have been reported; the present report is 
the fifth case. Clinicians must be aware of the possible side 
effects, including dystonia, when the stimulant compo-
nent of a psychostimulant and antipsychotic drug combi-
nation regimen is changed.
CASE
A male patient was referred to our clinic with com-
plaints of hyperactivity, disrespectful behaviors, and con-
tentiousness at 9 years of age. He was born at 37 weeks 
gestation by elective cesarean section and completed his 
developmental stages in an appropriate timeframe. He had 
no family history of psychiatric or physical illness and 
started primary school at 7 years of age. He learned to read 
and write during his first year of school, but his teacher 
complained about his not listening to lessons and talking 
loudly and arguing with his friends. An evaluation with 
the Conners Parent and Teacher Rating Scales confirmed 
the boy’s symptoms, and he was diagnosed with ADHD 
and conduct disorder. 
His initial treatment consisted of 27 mg of modi-
fied-release methylphenidate (MPH). One month later, 
the dose of MPH was increased to 36 mg, and 0.5 mg of 
risperidone was added due to his behavior problems. 
Although the child partially benefited from the treatment, 
his parents and teachers continued to have complaints 
about his behavior; specifically that the child was restless 
and irritable when the impact of MPH was no longer felt. 
Therefore, the risperidone dose was gradually increased to 
3 mg and divided into two doses; his most recent treatment 
116 G. Guler, et al.
regimen consisted of 54 mg of MPH and 3 mg of 
risperidone. After a long interval using this treatment regi-
men, the child was admitted to the emergency room with 
complaints of licking, tongue protrusion, and tension with 
difficulty closing his mouth. His neurological examina-
tion and blood tests, including electrolyte levels, were all 
in the normal range. Ultimately, it was learned that his 
symptoms began to appear 6-7 hours after he failed to take 
his MPH medication. He had always regularly taken both 
MPH and risperidone until that time, and whenever he for-
got his MPH medication, the same complaints recurred. 
He experienced these behavioral symptoms three times.
DISCUSSION
ADR is an extrapyramidal symptoms (EPS) charac-
terized by involuntary, transient, or permanent muscular 
contractions, especially in the head, neck, and face.3) ADR 
typically manifests within a few days after the initiation of 
an antipsychotic drug regimen; the risk factors include a 
young age, male gender, primary psychotic disorder, and 
previous dystonic reactions.3) In the present case, a patient 
was a child and male, which were thought to increase the 
risk of ADR.
MPH results in a downregulation of postsynaptic dop-
amine receptors via an increase in the amount of dopamine 
and noradrenaline, particularly of dopamine in the syn-
aptic cleft.4) Conversely, antipsychotics upregulate dop-
amine receptors by binding to postsynaptic D2 receptors.5) 
Although antipsychotics and MPH have opposite effects 
on the dopaminergic system,6) these drugs are often used 
in combination for the treatment of ADHD. 
The combination of psychostimulant and antipsychotic 
drugs has been reported to be safe and highly effective for 
the treatment of aggression in children and adolescents.7,8) 
However, in the present case, the uncommon occurrence 
of dystonia as a result of the sudden cessation of MPH dur-
ing combination therapy with risperidone was reported. 
Similar cases have been reported including four patients 
that experienced ADR when the stimulant component was 
removed from a regimen of antipsychotics and stimulants 
in combination.9,10) In another case, dystonia developed 
following a change in the stimulant dose when dextro-
amphetamine and an antipsychotic were used concur-
rently.11) Yet another case reported that ADR was asso-
ciated with an interruption in drug treatment during a regi-
men which included aripiprazole, a partial agonist of 
dopamine.2)
In the present case, EPS did not develop during con-
comitant use of risperidone and MPH; rather, the patient 
experienced ADR when he did not take the stimulant 
medication. The patient had taken MPH for 1 month prior 
to the initiation of risperidone, which raises the question; 
if the patient had received risperidone from the onset of 
treatment, would the ADR still have occurred? Dystonia is 
not an expected side effect of the discontinuation of MPH 
after the its concurrent use with risperidone for 2 months. 
A salient issue in this case is that ADR, which is highly 
likely to emerge in the first few days of antipsychotic treat-
ment,3) was observed after a long treatment interval. 
However, it is known that the abrupt cessation of stimulant 
treatment may lead to the development of movement dis-
orders,2,9-11) as in the present case. Moreover, a change in 
the dose of MPH is related to alterations in metabolic ac-
tivity in extrapyramidal system components such as the 
substantia nigra and subtalamica nucleus.12) 
It is possible that the etiology of acute EPS is associated 
with the discharge of dopamine in the synaptic cleft or ex-
cessive dopaminergic activity which cannot be blocked 
due to dopaminergic influences on hypersensitive dop-
amine receptors.13) Amphetamine, cocaine, and MPH 
have similar mechanisms of action, and amphetamine and 
cocaine use during antipsychotic treatment is a risk factor 
for dystonia.14,15) Therefore, when used in combination 
with antipsychotics, MPH may also increase the risk of 
ADR. Dystonia developed in a patient when MPH was 
added to a drug regimen that included aripiprazole.16) In 
this case, MPH seemed to initiate e EPS instead of pre-
venting it, whereas in the present case, MPH seemed to be 
protective against EPS.
The precise mechanisms underlying the manifestation 
of ADR remain unclear. However, the findings of the pres-
ent case study suggest that it would be beneficial to begin 
stimulant treatment at a low dose and to slowly and in-
crementally decrease stimulant doses when they are used 
in combination with antipsychotics, especially in children 
and adolescents.
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